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SUMMARY
Objective: To detect the frequency and subtypes of HPV in the uterine cervix of HIV-
infected women. Methods: Sample consisted of 288 HIV-infected women, recruited 
from the public health system of five cities of Minas Gerais, Brazil. Women were seen from 
August 2003 to August 2008. Cervical samples were collected for cytological analysis and 
for HPV DNA detection, using polymerase chain reaction (PCR). HPV DNA was classi-
fied according to its oncogenic potential in low risk (types 6, 11) and high risk (types 16, 
18, 31, 33, 35). Colposcopy was performed, followed by cervical biopsy when necessary. 
Categorical variables were compared using the Chi-squared test, with a significance lev-
el established at the 5% level. Results: HPV prevalence was 78.8%. Most frequent geno-
types were HPV-6 (63.9%) and HPV-16 (48.5%). High-risk HPV were observed in 70.5% 
of the women; low-risk in 71.4%; both high and low-risk HPV were detected in 55.1% of 
the patients. Multiple HPV genotypes were detected in 64.8% of the patients; two genotypes 
in 23.8%, and three in 18.9%. Conclusion: HPV prevalence was high among HIV-infected 
women. Multiple HPV genotypes were common in samples from the uterine cervix of HIV-
infected women.
Keywords: DNA probes, HPV; HIV; polymerase chain reaction; cervix uteri; papillomavirus 
infections, prevalence.
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INTRODUCTION
The association between cervical cancer and human im-
munodeficiency virus (HIV) is well established1,2. Several 
studies have shown that HPV infection is significantly 
more common among HIV positive women compared to 
HIV negative women3-10.
The association between cervical cancer and human 
papillomavirus (HPV) has also been demonstrated, but 
the potentially modifying role of HIV on the HPV/cer-
vical intraepithelial neoplasia association is still under 
investigation11. Current data suggest that HIV infection 
increases HPV persistence, with increased risk for in-
traepithelial cervical lesions2,4.
Published data strongly suggest that HIV-infected 
women are more likely to have HPV DNA, as well as mul-
tiple viral types and a higher frequency of the oncogenic 
types6-8. Similar findings have been reported in different 
regions of Brazil9,12-14 and HPV 16 was the most frequent 
oncogenic type7-9.
Polimerase chain reaction (PCR) has the highest sen-
sitivity for detecting HPV DNA genotypes and discrimi-
nates multiples infections better than other biomolecu-
lar methods. It also has good specificity and results are 
quickly available2.
The aim of this study was to estimate the prevalence 
of HPV DNA infection in HIV-infected women from dif-
ferent cities. We also aimed to investigate the prevalence 
of HPV genotypes, as well as the frequency of multiple 
types of HPV. 
METHODS
PATIENTS
Women attending a Reference and Training Center 
on Infectious and Parasitic Diseases in Belo Horizonte 
(Hospital das Clínicas, Universidade Federal de Minas 
Gerais - UFMG) and public health units of general gyne-
cological care of four other cities of Minas Gerais State 
(Betim, Barbacena, Conselheiro Lafaiete and Divinópolis) 
were randomly chosen to be enrolled in the study. This 
study was conducted from August 2003 to August 2008.
A standardized questionnaire was used for collecting 
demographic, social, and behavioral characteristics of 
the sample, as well as for obtaining the medical history. 
Gynecological exam was performed and cervical samples 
were collected for Pap smear, as well as for HPV-DNA, 
by doctors from the group study to guarantee a standard-
ized collection. Blood samples were collected to obtain 
T CD4+ cells count and HIV viral load. Colposcopy, bi-
opsy and adequate treatment of cervical lesions were per-
formed as part of the routine medical care.
Inclusion criteria were: HIV infection diagnosed 
by ELISA and confirmed by indirect immunofluores-
cence or western blot, with or without AIDS; age  ≥  18 
years; consent to participate (signature of the approved 
informed consent form). Exclusion criteria were: difficul-
ties in obtaining information (language barrier, disori-
entation); non-analyzable samples; pregnancy; history of 
hysterectomy.
The study protocol was approved by the UFMG Re-
search Ethics Committee.
PROCEDURES
Cervical samples for DNA-HPV exams were obtained us-
ing an Ayre’s spatula, and transferred to a sterile tube con-
taining 2 mL of saline solution (0.09%). The tube was con-
ditioned in a special box with cooled gel. The samples were 
sent to a reference laboratory (Núcleo de Ações e Pesquisas 
em Apoio Diagnóstico, Medical School, UFMG), within 24 
hours of the procedure. 
DNA was extracted using Chelex 100 chelating resin 
(BioRad), according to the manufacturer’s protocol15. Spe-
cific primers for HPV DNA types 6, 11, 16, 18, 31, 33 and 
35 were tested.
POLYMERASE CHAIN REACTION AND ANALYSIS CRITERIA
In order to control for DNA quality, the globin gene was 
amplified in all samples16. Globin-negative samples were 
excluded from the study. HPV detection by PCR was car-
ried out in a nested-PCR system, using MY09/1117 and 
GP5+/6+18 primers. Positive samples were tested with spe-
cific primers for HPV DNA types 6, 11, 16, 18, 31, 33 and 35, 
through independent reactions15.  All products were sub-
mitted to agarose gel electrophoresis 2%, treated with 
ethidium bromide and analyzed under UV light. DNA was 
classified according to its oncogenic potential in low risk 
(6, 11) and high risk (16, 18, 31, 33 and 35). 
STATISTICAL ANALYSIS
Data were transferred to a specially designed database us-
ing Excel 2003. Demographic and social variables included 
were: age (in years) at enrollment; age of first sexual inter-
course; lifetime number of sexual partners; marital status; 
working status; smoking; condom use; route of transmis-
sion; and drug addiction. Clinical and laboratory variables 
were: CDC classification (1993)19;  antiretroviral regimen 
use; colposcopy; CD4+ T-lymphocytes cell count; HIV-1 
viral load. Frequency and type of HPV genotypes (6, 11, 
16, 18, 31, 33 and 35) were also analyzed.
The Epi-Info software version 3.3.2 was used for the 
statistical analysis. Proportions were compared with 
the Chi-squared test. Statistical significance was es-
tablished at the 5% levels. Sample size was determined 
based on published findings (prevalence of HPV in 
HIV-infected women ranging from 52 to 87%)9,14. 
The prevalence of 50% was used in order to obtain a 
minimum sample that might guarantee more precise 
statistical tests. To achieve 80% of power, we estimated 
the sample at 278 participants.
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RESULTS 
The sample consisted of 288 women from five different cit-
ies: A (n = 152; 52.8%); B (n = 36; 12.5%); C (n = 20; 6.9%); 
D (n = 44; 15.3%); and E (n = 36; 12.5%).  As can be seen 
in Figure 1, general prevalence of HPV infection was high 
(78.8%) among these HIV-infected patients. There was no 
significant difference among HPV prevalence of women 
from these different cities (p = 0.19). 
Median age at enrollment was 35 years; median age 
of first sexual intercourse was 17 years; median number of 
lifetime sexual partners was three. Regarding the clinical 
and behavioral characteristics, most participants were in 
a stable union (44.1%), worked at home (51.7%) and were 
infected through the sexual route (92.0%). Few women 
smoked (31.3%), used condom (42.7%) and were addicted 
to drugs (0.7%). Half of them had AIDS19 and 67.7% were 
using antiretroviral drugs. Normal colposcopy was found 
in 63.2% of them. Table 1 summarizes some of the clinical 
and behavioral characteristics of these women.
It was detected that 151 patients presented a viral load 
higher than the established cut-off value of 400 copies/mL 
(minimum limit of detection of RNA HIV at the time of 
the study). Among them, in 123 (81.5%) was detected the 
DNA HPV. On the other hand, 119 patients had undetect-
ed viral load (≤ 400 copies/mL) and 90 (75.6%) of them 
presented the DNA HPV. The differences were not signifi-
cant (p = 0,2441).
Furthermore, a cut in the T CD4+ cell count in 
200 cells/mm3 was made based on the CDC classification 
of AIDS and non-AIDS19. Amongst 45 patients presenting 
T CD4+ cell count < 200 cells/mm3, 37 (82.2%) had the 
Figure 1 – DNA-HPV detection among women from five 
different cities in Minas Gerais, Brazil.
Clinical and behavioral 
characteristics
City A
(n = 152)
City B
(n = 36)
City C
(n = 20)
City D
(n = 44)
City E
(n = 36)
Overall
(n = 288)
p*
n (%) n (%) n (%) n (%) n (%) n (%)
CDC classification 0.46
AIDS 74 (48.7) 17 (47.2) 13 (65) 21 (47.7) 19 (52.8) 144 (50)
Not AIDS 75 (49.3) 19 (52.8) 5 (25) 20 (45.5) 17 (47.2) 136 (47.2)
Missing 3 (2) 0 (0) 2 (10) 3 (6.8) 0 (0) 8 (2.8)
Antiretroviral drugs 0.67
Use 101 (66.4) 22 (61.1) 14 (70) 32 (72.7) 26 (72.2) 195 (67.7)
Not use 51 (33.6) 14 (38.9) 5 (25) 11 (25) 10 (27.8) 91 (31.6)
Missing 0 (0) 0 (0) 1 (5) 1 (2.3) 0 (0) 2 (0.7)
Colposcopy 0.68
Normal 99 (65.1) 19 (52.8) 12 (60) 30 (68.2) 22 (61.1) 182 (63.2)
Abnormal 50 (32.9) 16 (44.4) 8 (40) 14 (31.8) 13 (36.1) 101 (35.1)
Missing 3 (2) 1 (2.8) 0 (0) 0 (0) 1 (2.8) 5 (1.7)
Condom 0.23
Use 60 (39.5) 13 (36.1) 7 (35) 22 (50) 21 (58.3) 123 (42.7)
Not use 84 (55.3) 23 (63.9) 13 (65) 22 (50) 15 (41.7) 157 (54.5)
Missing 8 (5.3) 0 (0) 0 (0) 0 (0) 0 (0) 8 (2.8)
Route of HIV acquisition 0.23
Sexual 140 (92.1) 31 (86.1) 19 (95) 39 (88.6) 36 (100) 265 (92)
Blood 0 (0) 1 (2.8) 0 (0) 1 (2.3) 0 (0) 2 (0.7)
Missing 12 (7.9) 4 (11.1) 1 (5) 4 (9.1) 0 (0) 21 (7.3)
*X² test (4 df).
Table 1 – Clinical and behavioral characteristics of women
City A
(n = 152)
City B
(n = 36)
City C
(n = 20)
City D
(n = 44)
City E
(n = 36)
Total
(n = 288)
 Negative 23.0% 13.9% 25.0% 11.4% 30.6% 21.2%
 Positive 77.0% 86.1% 75.0% 88.6% 69.4% 78.8%
0
20
40
Heterogeneity: X2 = 6.07 (4df). p = 0.19
60
80
%
100
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DNA HPV. On the other hand, 226 patients had T CD4+ 
cell count ≥ 200 cells/mm3 and 177 (78.3%) of them pre-
sented the DNA HPV. The differences were not significant 
either (p = 0.5574). 
High-risk HPV (patient showing at least one high-
risk HPV type) was observed in 70.5% (160/288) of pa-
tients; low-risk HPV (patient showing at least one low-risk 
HPV type) was found in 71.4% (162/288) of women; 
and both high and low-risk HPV were detected in 55.1% 
(125/288) of them. The prevalence of HPV was higher 
(61.7%) in patients who had three or more sexual partners. 
Nevertheless, this result was not significant (p = 0.8431).
Table 2 displays the prevalence of each genotype as 
well as the proportion of women with multiple HPV geno-
types. Most prevalent genotypes were HPV-6 (63.9%) and 
HPV-16 (48.5%). Differences emerged among cities. 
HPV-31 and HPV-33 genotypes were the most prevalent 
in City C (60% and 53.3%) and City E (24% for both). 
Multiple genotypes were present in 64.8% of women: two 
(23.8%) and three (18.9%) different genotypes were com-
mon. This table also shows that the percentage of patients 
with HPV which could not be typed varied from 0% to 
11.1%. One of the cities (City E) presented the highest per-
centage of non-identified HPV (48%). 
DISCUSSION
Prevalence of HPV infection was high (78.8%) among our 
sample of HIV-infected patients recruited at five different 
cities. These findings are consisted with other studies6,14,20. 
Median age (35 years old) was similar to the age of a 
distinct sample in Brazil14,21. That suggests that HPV/HIV 
coinfection is common among women of reproductive age.
Although the median age for the first sexual intercourse 
was 17, dispersion was high and some women had first 
sexual intercourse as early as at the age of 10, as previously 
described8. 
Sexual transmission was the predominant route of HIV 
acquisition (92%), at higher rates than previously reported22. 
Condom use was not a common practice, consistently used 
by only 42.7% of the partners. Similar percentage has been 
previously reported in a sample of 75 HIV-infected patients22. 
Data obtained from a metanalysis from different coun-
tries of North America, Africa, Asia, Europe and South/
Central America evaluated prevalence of HPV and geno-
types among 5.578 HIV-infected patients. South and North 
America (Brazil and Mexico) contributed 7.8% of the sam-
ple. HPV prevalence was higher among women from Brazil 
and Mexico (57.3%), compared to overall findings (36.5%). 
According to this metanalysis, HPV prevalence was asso-
ciated with advanced cervical lesion. Multiple infections 
were frequent, and HIV-positive patients with HPV-16 were 
more likely to have advanced cervical lesions7. 
In addition, studies conducted in Brazil9 and India8 
found that HPV-16 was the most common genotype (30.9% 
and 33% respectively) among HIV-infected women. We 
found that HPV-6 was the most prevalent genotype (63.9%), 
followed by HPV-16 (48.5%). Other studies found percent-
ages ranging from 52% 6 to 87%9. 
HPV
Frequency and multiplicity
City A 
(n = 117)
City B
(n = 31)
City C
(n = 15)
City D
(n = 39)
City E
(n = 25)
All cities 
(n = 227)
  n % n % n % n % n % n %
No genotyping 13 11.1 3 9.7 0 0.0 2 5.1 12 48.0 30 13.2
Genotyping 104 88.9 28 90.3 15 100 37 94.9 13 52 197 86.8
HPV-6 82 70.1 23 74.2 8 53.3 31 79.5 1 4.0 145 63.9
HPV-11 39 33.3 10 32.3 6 40.0 14 35.9 2 8.0 71 31.3
HPV-16 60 51.3 17 54.8 5 33.3 26 66.7 2 8.0 110 48.5
HPV-18 7 6.0 2 6.5 1 6.7 2 5.1 1 4.0 13 5.7
HPV-31 10 8.5 2 6.5 9 60.0 4 10.3 6 24.0 31 13.7
HPV-33 25 21.4 6 19.4 8 53.3 11 28.2 6 24.0 56 24.7
HPV-35 48 41.0 15 48.4 6 40.0 17 436 3 12.0 89 39.2
Simple infection 24 20.5 7 22.6 4 26.7 7 17.9 8 32.0 50 22.0
Multiple infection 80 68.4 21 67.7 11 73.3 30 76.9 5 20.0 147 64.8
2 types 32 27.4 6 19.4 4 26.7 9 23.1 3 12.0 54 23.8
3 types 23 19.7 8 25.8 2 13.3 9 23.1 1 4.0 43 18.9
4 types 13 11.1 4 12.9 2 13.3 8 20.5 1 4.0 28 12.3
≥ 5 types 12 10.3 3 9.7 3 20.0 4 10.3 0 0.0 22 9.7
HPV, human papillomavirus; PCR, polimerase chain reaction; HIV, human immunodeficiency virus.
Table 2 – Frequency and multiplicity of HPV genotypes in cervical samples of 227 HPV-infected women
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The proportion of patients with non-identified HPV 
was 13.2%, with the highest frequency from City E (48%). 
The small number of types investigated in addition to the 
great variety of types present in these patients may ex-
plain differences among reported prevalences23,24. We did 
not test all genotypes of HPV, what is one of the limita-
tions of our study. Besides, comparison among cities was 
merely descriptive, as the sample was not calculated for 
this purpose and the goal was only to detect the frequen-
cy and subtypes of HPV in the uterine cervix of HIV-
infected women from different cities of Minas Gerais.
Number of sexual partners and alcohol consumption 
were the most significant risk factors for HPV infection, 
followed by young age and lower income in a sample of 
225 Greek women attending a gynecological outpatient 
clinic25. On the contrary, we did not find any association 
between HPV prevalence and risk factors, such as un-
protected sexual intercourse, number of sexual partners, 
HIV viral load and T CD4+ cell count, likely reflecting 
power limitations. Furthermore, we did not have access 
to longitudinal data for immunological status and HIV 
viral load. 
According to our results the higher the HIV viral 
load was the more prevalent (81.5%) the HPV. How-
ever, these findings were not statistically significant 
(p  >  0.05). There was a trend among patients with 
T CD4+ cell count < 200 cells/mm3, to present a higher 
rate of HPV infection (82.2%). Once more the result 
was not significant (p > 0.05). Most likely the follow-up 
of HIV-infected women – including PCR for detecting 
HPV on the cervix uteri associated with T CD4+ cells 
count and viral load quantification – could allow better 
evaluation between HPV cervical infection and low im-
munity in these patients11.
An important finding was the high prevalence of mul-
tiple HPV types7,9, which was found in 64.8% of women. 
Different percentages of multiple HPV genotypes were 
found by other authors – 36%26, 45%9 and 52%6 – likely 
explained by different methods of HPV genotyping, as 
well as different primers used for detection.
Our results differ from the findings of Cuschieri et al.26 
These authors performed PCR in 3,444 patients, and 
HPV infection was found in only 20% of participants. 
Multiple infections with at least one high risk HPV gen-
otype were found in 23.3% (164/705) of cases, low risk 
HPV in 0.8% (6/705) and both high and low risk HPV in 
19.3% (136/705), rates much lower than ours. Nonethe-
less, the lack of stratification for HIV status may explain 
this discrepancy.
The presence of multiple HPV genotypes can be ex-
plained by the reactivation of latent HPV types with su-
perimposed new infection, driven by unprotected sexual 
intercourse and also perhaps by the long period of data 
collection of our study. They may also reflect failure of 
immunological response. We evaluated the T CD4+ cell 
counts, but did not measure local immune response. 
However, the mechanism of the HIV/HPV association 
can be only speculated at this time.
CONCLUSION
Although our study assessed women from a single state, 
data may reflect the situation of HIV-infected women in 
Brazil overall. We confirmed the high prevalence of HPV 
and of multiple HPV infections in samples from the uter-
ine cervix of HIV-infected women. Our data also dem-
onstrated the importance of studying subpopulations in 
order to plan adequate preventive programs. 
 
REFERENCES
1. Zur Hausen H. Papillomaviruses in the causation of human cancers 
- a brief historical account. Virology 2009;384:260-5.
2. Thomison III J, Thomas LK, Shroyer KR. Human papilloma-
virus: molecular and citologic/histologic aspects related to 
cervical intraepithelial neoplasia and carcinoma. Hum Pathol 
2008;39:154-66.
3. Lima MIM, Tafuri A, Araújo AC, Lima LM, Melo VH. Cervical in-
traepithelial neoplasia recurrence after conization in HIV-positive 
and HIV-negative women. Int J Gynaecol Obstet 2009;104:100-4.
4. Lehtovirta P, Paavonen J, Heikinheimo O. Risk factors, diagnosis 
and prognosis of cervical intraepithelial neoplasia among HIV-
infected women. Int J STD AIDS 2008;19:37-41.
5. Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N 
et al. Worldwide prevalence and genotype distribution of cervical 
human papillomavirus DNA in women with normal cytology: a 
meta-analysis. Lancet Infect Dis 2007;7:453-59.
6. Luque AE, Jabeen M, Messing S, Lane CA, Demeter LM, Rose RC 
et al. Prevalence of human papillomavirus genotypes and related 
abnormalities of cervical cytological results among HIV-1-Infected 
Women in Rochester, New York. J Infect Dis 2006;194:428-34.
7. Clifford GM, Gonçalves MAG, Franceschia S. Human papillomavi-
rus types among women infected with HIV: a meta-analysis for the 
HPV and HIV Study Group. AIDS 2006;20:2337-44.
8. Joshi SN, Gopalkrishna V, Kumar BK, Dutta S, Nyaynirgune, Tha-
kar M et al. Cervical squamous intra-epithelial changes and human 
papillomavirus infection in women infected with human immuno-
deficiency virus in Pune, India. J Med Virol 2005;76:470-5. 
9. Levi JE, Fernandes S, Tateno AF, Motta E, Lima LP, Neto JE et al. 
Presence of multiple human papillomavirus types in cervical sam-
ples from HIV-infected women. Gynecol Oncol 2004;92:225-31.
10. Averbach SH, Gravitt PE, Nowak RG, Celentano DD, Dunbar MS, 
Morrison CS et al. The association between cervical human papil-
lomavirus infection and HIV acquisition among women in Zimba-
bwe. AIDS 2010;24:1035-42.
11. Cejtin HE. Gynecologic issues in the HIV-infected woman. Infect 
Dis Clin North Am 2008;22:709-39.
12. Tozetti IA, Scapulatempo IDL, Kawski VL, Ferreira W, Levi 
JE. Multiple types of Human Papillomavirus in cervical sam-
ples in women in Campo Grande, Brazil. Braz J Infect Dis 
2006;10:309-10. 
13. Campos A, Amaral E, Levi JE, Portugal P, Villarroel M, Bezerra KC 
et al. HIV vaginal viral load in brazilian hiv-infected women. Rev 
Assoc Med Bras 2008;54:67-71. 
14. Levi JE, Kleter B, Quint WG, Fink MC, Canto CL, Matsubara R 
et al. High prevalence of human papillomavirus (HPV) infections 
and high frequency of multiple HPV genotypes in human im-
munodeficiency virus-infected women in Brazil. J Clin Microbiol 
2002;40:3341-5.
15. Walsh PS, Metzger DA, Higuchi R. Clelex 100 as a medium for 
simple extraction of DNA for PCR-based typing from forensic ma-
terial. Biotechniques 1991;10:606-13.
PREVALENCE AND MULTIPLICITY OF HPV IN HIV WOMEN IN MINAS GERAIS, BRAZIL
423Rev Assoc Med Bras 2011; 57(4):418-423
16. Duggan MA, Inoue M, McGregor SE, Stuart GC, Morris S, Chang-
Poon V et al. A paired comparison of dot blot hybridization and PCR 
amplification for HPV testing for cervical scrapes interpreted as CIN 
1. Eur J Gynaecol Oncol 1994;15:178-87.
17. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM 
et al. The use of polymerase chain reaction amplification for the detec-
tion of genital human papillomavirus. Cancer Cells 1989;88:209-14.
18. Roda Husman A-M, Walboomers JMM, Van den Brule AJC, Mei-
jer CJLM, Snijders PJF. The use of general primers GP5 and GP6 
elongated at their 3’ ends with adjacent highly conserved sequenc-
es improves human papillomavirus detection by PCR J Gen Virol. 
1995;76:1057-62. 
19. CDC. Centers for Disease Control and Prevention. Revised classifi-
cation system for HIV infection and expanded surveillance case defi-
nition for AIDS among adolescents and adults. MMWR Recomm 
Rep 1993;41(RR-17):1-19.
20. Levi G, Feldman J, Holman S, Salarieh A, Strickler HD, Alter S et 
al. Relationship between HIV viral load and Langerhans cells of the 
cervical epithelium. J Obstet Gynaecol Res 2005;31:178-84.
21. Valadares ALR, Mendes A, Neto P, Abdo C, Melo VH. HIV in middle-
aged women: associated factors. Rev Assoc Med Bras 2010;56:112-5.
22. Nappi L, Carriero C, Bettocchi S, Herrero J, Vimercati A, Putig-
nano G. Cervical squamous intraepithelial lesions of low-grade in 
HIV-infected women: recurrence, persistence, and progression, in 
treated and untreated women. Eur J Obstet Gynecol Reprod Biol 
2005;121:226-32.
23. Carvalho NO, Castillo DM, Perone C, Januário JN, Filho B, Melo 
VH. Comparison of HPV genotyping by type-specific PCR and se-
quencing. Mem Inst Oswaldo Cruz 2010;105:73-8.
24. Freitas TP, Carmo BB, Paula FDF, Rodrigues LF, Fernandes AP, 
Fernandes PA. Molecular detection of HPV 16 and 18 in cervical 
samples of patients from Belo Horizonte, Minas Gerais, Brazil. Rev 
Inst Med Trop São Paulo 2007;49:297-301.
25. Stamataki P, Papazafiropoulou A, Elefsiniotis L, Giannakopoulou 
M, Brokalaki H, Apostolopoulou E et al. Prevalence of HPV in-
fection among Greek women attending a gynecological outpatient 
clinic. BMC Infect Dis 2010;10:27.
26. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, 
Moore C et al. Multiple high risk HPV infections are common in 
cervical neoplasia and young women in a cervical screening popu-
lation. J Clin Pathol 2004;57:68-72.
